Crossmark

Efficacy and safety of inhaled ambroxol hydrochloride solution in patients with lower respiratory tract infectious diseases: a randomized, double-blind, placebo-controlled, multicentre clinical trial

Crossref DOI link: https://doi.org/10.1186/s12879-025-11194-w

Published Online: 2025-07-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Di

Fu, Xiuhua

Jin, Faguang

Li, Hui

Qin, Zhiqiang

Wang, Haoyan

Yue, Hongmei

Zhang, Jie

Cao, Zhaolong
License Information

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-07-01
More Information

Article History

Received: 13 August 2024

Accepted: 2 June 2025

First Online: 1 July 2025

Declarations

:

: Patients signed the informed consent. The Ethics Committee of Peking University People’s Hospital approved the trial with the Ethics number of 2013-21. The trial was registered on Chinese Clinical Trial Registry with the number of ChiCTR2300072467.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below